La Jolla Pharmaceutical Company secured FDA approval for ZEVTERA (ceftobiprole medocaril sodium), positioning itself in the IV antibiotic market to address resistant bacterial infections. Investors view the clearance as a positive catalyst for growth and valuation, offering a potential revenue stream in the high-stakes hospital setting.